Moreover, GCN2 inhibition might be most effective in sensitising cancer cells in nutrient-poor tumour areas to drugs that affect amino acid metabolism, such as proteasome inhibitors or l-asparaginase, without relevant toxic effects on normal tissues. The gene discussed is EIF2AK4; the disease is cancer.